MX386918B - Coadyuvantes basados en aceite. - Google Patents

Coadyuvantes basados en aceite.

Info

Publication number
MX386918B
MX386918B MX2016003658A MX2016003658A MX386918B MX 386918 B MX386918 B MX 386918B MX 2016003658 A MX2016003658 A MX 2016003658A MX 2016003658 A MX2016003658 A MX 2016003658A MX 386918 B MX386918 B MX 386918B
Authority
MX
Mexico
Prior art keywords
oil
based adjuvants
tlr
glycolipids
saponins
Prior art date
Application number
MX2016003658A
Other languages
English (en)
Other versions
MX2016003658A (es
Inventor
Anita Dorota Jaglarz
Paul Joseph Dominowski
David George Emslie Smith
Dennis L Foss
Guillermo Gallo
John Morgan Hardham
Julie Lydia Fitzpatrick
Richard Lee Krebs
Kaori Mohr
Lauren Wilmes
Sangita Mediratta
Duncan Mwangi
Michael Christopher Fontaine
Sharath K Rai
Sandra Ann Marie Lightle
Sarah A Salmon
Shaunak Vora
Suman Mahan
William Donachie
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2016003658A publication Critical patent/MX2016003658A/es
Publication of MX386918B publication Critical patent/MX386918B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)

Abstract

La presente invención ser refiere a proporciona diversas formulaciones que comprenden combinaciones de oligonucleótidos inmunoestimulantes, vehículos policatiónicos, esteroles, saponinas, aminas cuaternarias, agonistas de TLR-3, glicolípidos y MPL-A o análogos del mismo en emulsiones en aceite, el uso de las mismas en preparaciones de composiciones inmunogénicas y vacunas y el uso de las mismas en el tratamiento de animales.
MX2016003658A 2013-09-19 2014-09-19 Coadyuvantes basados en aceite. MX386918B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361879959P 2013-09-19 2013-09-19
PCT/US2014/056512 WO2015042369A2 (en) 2013-09-19 2014-09-19 Oil-based adjuvants

Publications (2)

Publication Number Publication Date
MX2016003658A MX2016003658A (es) 2016-06-24
MX386918B true MX386918B (es) 2025-03-19

Family

ID=51663499

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016003658A MX386918B (es) 2013-09-19 2014-09-19 Coadyuvantes basados en aceite.
MX2021012346A MX2021012346A (es) 2013-09-19 2016-03-18 Coadyuvantes basados en aceite.
MX2021005619A MX2021005619A (es) 2013-09-19 2016-03-18 Coadyuvantes basados en aceite.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2021012346A MX2021012346A (es) 2013-09-19 2016-03-18 Coadyuvantes basados en aceite.
MX2021005619A MX2021005619A (es) 2013-09-19 2016-03-18 Coadyuvantes basados en aceite.

Country Status (16)

Country Link
US (6) US10117921B2 (es)
EP (2) EP3049105B1 (es)
JP (7) JP6586083B2 (es)
KR (4) KR101943171B1 (es)
CN (4) CN105764525A (es)
AU (5) AU2014321369B2 (es)
BR (1) BR112016005948A2 (es)
CA (4) CA3005608C (es)
CL (3) CL2016000650A1 (es)
MX (3) MX386918B (es)
NZ (3) NZ757210A (es)
PH (1) PH12016500456A1 (es)
RU (1) RU2730011C2 (es)
UA (1) UA121200C2 (es)
WO (3) WO2015042369A2 (es)
ZA (3) ZA201601840B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3730148A3 (en) * 2012-12-28 2021-03-24 Boehringer Ingelheim Vetmedica GmbH Immunogenic composition comprising mycoplasma antigens
NZ757210A (en) * 2013-09-19 2022-12-23 Zoetis Services Llc Oil-based adjuvants
BR112016012127A2 (pt) 2013-11-26 2017-09-26 Zoetis Services Llc composições para a indução da resposta imunológica
SI3166634T1 (sl) 2014-07-11 2021-11-30 Zoetis Services Llc Sestave novih cepiv za virus prašičje epidemične diareje
AR103427A1 (es) * 2015-01-16 2017-05-10 Zoetis Services Llc Vacuna contra la fiebre aftosa
KR20170105105A (ko) * 2015-01-27 2017-09-18 쓰리엠 이노베이티브 프로퍼티즈 컴파니 마이크로니들 백신 패치를 위한 명반-함유 코팅 제형
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
RU2736642C2 (ru) * 2015-07-20 2020-11-19 Зоэтис Сервисиз Ллс Липосомальные адъювантные композиции
CN106421775B (zh) * 2015-08-12 2020-12-01 普莱柯生物工程股份有限公司 一种疫苗用佐剂及含该佐剂的疫苗组合物和其应用
CA3010977A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
MX387200B (es) 2016-02-15 2025-03-18 Hipra Scient S L U Extracto de streptococcus uberis como agente inmunogénico.
WO2017165366A1 (en) 2016-03-21 2017-09-28 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery
CA3175832A1 (en) 2016-06-02 2017-12-07 Zoetis Services Llc Composition comprising infectious bursal disease antigens, immunostimulatory oligonucleotides in an oil emulsion
WO2018115229A1 (en) 2016-12-22 2018-06-28 Intervet International B.V. Eimeria vaccine with improved efficacy
KR101996538B1 (ko) * 2017-02-13 2019-07-04 단디바이오사이언스 주식회사 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
GB201718251D0 (en) * 2017-11-03 2017-12-20 Univ Sydney Vaccine Compositions
CN117323424A (zh) * 2017-12-20 2024-01-02 硕腾服务有限责任公司 针对亨德拉和尼帕病毒感染的疫苗
CN108553479A (zh) * 2018-04-03 2018-09-21 南京大学 阳离子修饰的琼脂糖和核酸药物组合物及制备方法和应用
CN108853493A (zh) * 2018-07-26 2018-11-23 中国人民解放军陆军军医大学 麦冬皂苷d及其纳米乳在制备疫苗佐剂中的应用
CA3107319A1 (en) 2018-07-27 2020-01-30 Research Development Foundation Chimeric immunogenic polypeptides
CN110967482B (zh) * 2018-09-30 2023-04-07 重庆市畜牧科学院 一种山羊化脓隐秘杆菌感染检测试剂盒及其检测方法
CN109675028A (zh) * 2019-03-01 2019-04-26 龙阔（苏州）生物工程有限公司 疫苗佐剂及其制备方法和应用及猪繁殖与呼吸综合征疫苗
KR102285977B1 (ko) 2019-03-15 2021-08-05 대한민국 오일 에멀젼과 병용 투여 가능한 면역증강용 보조물질 및 이를 포함하는 구제역 백신 조성물
BR112022000347A2 (pt) * 2019-07-12 2022-04-12 Res Found Dev Vacinas de ehrlichia e composições imunogênicas
US20220249650A1 (en) * 2019-07-15 2022-08-11 South Dakota Board Of Regents Senecavirus a virus strains and immunogenic compositions therefrom
BR112022000626A2 (pt) * 2019-07-30 2022-03-03 Phibro Animal Health Corporation Composição para administração mucosal a aves
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
TWI884296B (zh) * 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CN112611864B (zh) * 2020-12-03 2024-03-12 重庆市畜牧科学院 筛分病菌模型的系统及筛分方法
EP4259197A1 (en) * 2020-12-11 2023-10-18 ACM Biolabs Pte Ltd Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
CN114015621B (zh) * 2021-12-13 2022-04-26 云南农业大学 一种降解α-茄碱的谷氨酸杆菌GH202103菌株及其制备方法和应用
WO2024194885A1 (en) * 2023-03-21 2024-09-26 Indian Council Of Agricultural Research Vaccine compositions and methods for control of foot and mouth disease
US12226468B2 (en) 2023-06-26 2025-02-18 Research Development Foundation Immunoreactive peptides
CN116747312B (zh) * 2023-07-21 2025-08-08 辽宁成大生物股份有限公司 一种疫苗冻干保护剂、制剂及制备方法
CN119925590A (zh) * 2025-04-08 2025-05-06 北京华诺泰生物医药科技有限公司 一种mpl复合佐剂及其制备方法和应用

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
ATE60999T1 (de) 1986-12-19 1991-03-15 Duphar Int Res Dimethyldioctadecylammoniumbromid enthaltende stabilisierte adjuvanssuspension.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
RU1615918C (ru) 1989-05-22 1995-07-09 Всероссийский научно-исследовательский институт защиты животных Адъювант
GB8921470D0 (en) * 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
ZA978434B (en) * 1996-09-27 1998-03-26 Akzo Nobel Nv Inactivated vaccines.
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US20100267012A1 (en) * 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE441432T1 (de) 1997-03-10 2009-09-15 Ottawa Hospital Res Inst Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
WO1998048835A1 (en) 1997-04-30 1998-11-05 Merieux Oravax Anti-helicobacter vaccine composition for use by the subdiaphragmatic systemic route, and combined mucosal/parenteral immunization method
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
JP2002514397A (ja) 1998-05-14 2002-05-21 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP1574210B1 (en) 1999-02-26 2016-04-06 Novartis Vaccines and Diagnostics, Inc. Microemulsions with adsorbed macromolecules
JP4932086B2 (ja) 1999-04-08 2012-05-16 インターセル ユーエスエイ、インコーポレイテッド 経皮的免疫のための乾燥製剤
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
PL203951B1 (pl) * 1999-04-19 2009-11-30 Smithkline Beecham Biolog Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
ATE275727T1 (de) 1999-04-29 2004-09-15 Coley Pharm Gmbh Screening nach modulatoren der funktion von immunstimulatorischer dna
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1311288A1 (en) 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
ME00183B (me) 2000-02-21 2011-02-10 Pharmexa As Novi postupak za deregulaciju amiloida
CA2407942A1 (en) 2000-05-01 2001-11-08 Hybridon, Inc. Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
IL155282A0 (en) * 2000-10-18 2003-11-23 Glaxosmithkline Biolog Sa Vaccines
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
AU1412702A (en) * 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
DE60134421D1 (de) 2000-12-08 2008-07-24 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
EP1372528B1 (en) 2001-04-05 2013-01-02 Novartis Vaccines and Diagnostics, Inc. Mucosal boosting following parenteral priming
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
AU2002320762B2 (en) 2001-05-21 2006-09-21 Intercell Ag Immunostimulatory oligodeoxynucleic molecules
AU2002312487A1 (en) 2001-06-15 2003-01-02 Ribapharm Nucleoside vaccine adjuvants
MXPA03011924A (es) 2001-07-02 2004-03-26 Pfizer Prod Inc Vacuna de micoplasma hyopneumoniae y metodos para reducir la neumonia por mycoplasma bovis en el ganado.
CN102872456B (zh) 2001-07-02 2016-01-20 硕腾服务有限责任公司 单剂量猪肺炎支原体疫苗
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US20030072762A1 (en) 2001-08-03 2003-04-17 Van De Winkel Jan G. J. Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance Fc receptor-mediated immunotherapies
WO2003014316A2 (en) 2001-08-07 2003-02-20 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
US20030138434A1 (en) 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
NZ552377A (en) 2001-08-17 2008-08-29 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
JP2005500845A (ja) 2001-08-28 2005-01-13 ファイザー・プロダクツ・インク マイコプラズマ・ボビスチャレンジモデル並びにマイコプラズマ・ボビスの投与方法及び肺炎性肺病変の誘発方法
CA2492826C (en) 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
US20030119774A1 (en) 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
US20050238660A1 (en) 2001-10-06 2005-10-27 Babiuk Lorne A Cpg formulations and related methods
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US20030125292A1 (en) 2001-11-07 2003-07-03 Sean Semple Mucoscal vaccine and methods for using the same
EP1450821A1 (en) 2001-12-07 2004-09-01 Intercell AG Immunostimulatory oligodeoxynucleotides
EP1474432A1 (en) 2002-02-04 2004-11-10 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
JP2005517422A (ja) 2002-02-19 2005-06-16 シンセリカ・コーポレイション 代替抗体ならびにその調製方法および使用
ES2543710T3 (es) 2002-04-04 2015-08-21 Zoetis Belgium S.A. Oligorribonucleótidos inmunoestimulantes que contienen G y U
WO2003089590A2 (en) 2002-04-16 2003-10-30 Vaxin, Inc. TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH
KR101092043B1 (ko) 2002-04-22 2011-12-12 바이오니취 라이프 사이언시즈 인코포레이티드 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
KR100456681B1 (ko) 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
AU2003246396B2 (en) 2002-05-28 2008-08-21 Merck Patent Gmbh A method for generating antigen-presenting cells
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US20040009949A1 (en) 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
SE0201701D0 (sv) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
EP1575504A4 (en) 2002-08-01 2009-11-04 Us Gov Health & Human Serv METHOD FOR THE TREATMENT OF INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF THE CPG OLIGONUCLEOTIDES
TWI314134B (en) 2002-11-05 2009-09-01 James Hardie Int Finance Bv Calcium silicate hydrate and the method for producing the same
AU2004208556B2 (en) 2003-01-29 2009-06-04 Zoetis Services Llc Canine vaccines against bordetella bronchiseptica
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
ZA200507562B (en) 2003-03-26 2006-11-29 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
PL1613346T3 (pl) 2003-04-04 2013-03-29 Zoetis Services Llc Poddane mikrofluidyzacji emulsje typu olej w wodzie i kompozycje szczepionek
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
BRPI0509606B1 (pt) 2004-04-05 2019-01-15 Pah Usa 15 Llc emulsões de óleo-em-água microfluidizadas e composições para vacinas
US7749520B2 (en) 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
WO2006002642A2 (en) * 2004-07-07 2006-01-12 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
CA2604488A1 (en) 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
DK1991266T3 (da) 2006-01-26 2013-08-26 Zoetis P Llc Nye glycolipid-adjuvant-sammensætninger
WO2007125940A1 (ja) * 2006-04-25 2007-11-08 Kyowa Hakko Kogyo Co., Ltd. ネコノミ成虫由来ポリペプチド
MX2009003398A (es) * 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
US20080292663A1 (en) 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
CL2008001806A1 (es) * 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
EP2023143A1 (en) * 2007-08-06 2009-02-11 Boehringer Ingelheim Vetmedica Gmbh Immunogenic streptococcus proteins
EP2326344A4 (en) * 2008-06-16 2013-08-07 Prokarium Ltd VACCINES WITH SALMONELLA VECTOR AGAINST CHLAMYDIA AND METHOD OF ADMINISTRATION
NZ621834A (en) * 2008-06-27 2015-10-30 Zoetis Services Llc Novel adjuvant compositions
GB0818231D0 (en) * 2008-10-06 2008-11-12 Univ Nottingham Composition
CN101721698B (zh) 2008-10-24 2014-04-02 法罗斯疫苗公司 抗口蹄疫疫苗组合物及其制备和应用
JP6008345B2 (ja) 2009-02-27 2016-10-19 東レ株式会社 免疫原性組成物
WO2011112906A2 (en) * 2010-03-12 2011-09-15 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
CN103025351B (zh) * 2010-05-28 2016-08-24 佐蒂斯比利时股份有限公司 包含胆固醇和作为唯一的佐剂-载剂分子的cpg的疫苗
US8765141B2 (en) * 2010-07-01 2014-07-01 The United States Of America, As Represented By The Secretary Of Agriculture Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host
CN101954080B (zh) 2010-09-21 2013-11-06 中国农业科学院兰州兽医研究所 一种猪口蹄疫苗用的复合分子型佐剂及其制造方法
EP3858381A1 (en) 2011-02-04 2021-08-04 Zoetis Services LLC Immunogenic bordetella bronchiseptica compositions
CN110680913A (zh) * 2011-05-13 2020-01-14 硕腾有限公司 亨德拉和尼帕病毒g糖蛋白免疫原性组合物
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
GB201111183D0 (en) 2011-06-30 2011-08-17 Animal Health Inst Peptide
US10420832B2 (en) 2012-11-16 2019-09-24 United Biomedical, Inc. Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD)
CN103083663B (zh) 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
US10357470B2 (en) * 2013-03-07 2019-07-23 Kane Biotech Inc. Antimicrobial-antibiofilm compositions and methods of use thereof
MX2015011613A (es) * 2013-03-07 2016-08-08 Kane Biotech Inc Composiciones antimicrobianas-antibiopelicula y metodos para utlizarlas.
WO2014154655A1 (en) 2013-03-26 2014-10-02 The Pirbright Institute Stabilised fmdv capsids
HK1224177A1 (zh) * 2013-09-05 2017-08-18 硕腾服务有限责任公司 Hendra和nipah病毒g糖蛋白免疫原性組合物
NZ757210A (en) * 2013-09-19 2022-12-23 Zoetis Services Llc Oil-based adjuvants
CN104013955B (zh) * 2014-06-18 2016-02-24 中国科学院过程工程研究所 一种不含表面活性剂的水包油乳液及其用途
RU2593718C1 (ru) 2015-03-16 2016-08-10 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Вакцина инактивированная эмульсионная против ящура типов а, о, азия-1

Also Published As

Publication number Publication date
US20150140034A1 (en) 2015-05-21
US10744192B2 (en) 2020-08-18
EP3049105A2 (en) 2016-08-03
US20240000913A1 (en) 2024-01-04
UA121200C2 (uk) 2020-04-27
KR20180024030A (ko) 2018-03-07
MX2016003658A (es) 2016-06-24
ZA201903401B (en) 2024-09-25
NZ717594A (en) 2017-07-28
JP7675048B2 (ja) 2025-05-12
US11701415B2 (en) 2023-07-18
CN109675025A (zh) 2019-04-26
US20160193318A1 (en) 2016-07-07
US12121576B2 (en) 2024-10-22
JP7181847B2 (ja) 2022-12-01
JP2022121437A (ja) 2022-08-19
US10117921B2 (en) 2018-11-06
MX2021005619A (es) 2021-08-11
RU2019128165A (ru) 2019-10-10
AU2022268311B2 (en) 2025-01-23
AU2014321369B2 (en) 2020-04-16
KR20160057465A (ko) 2016-05-23
CL2018000319A1 (es) 2018-06-08
EP3046580A2 (en) 2016-07-27
NZ733383A (en) 2022-12-23
CN109675026A (zh) 2019-04-26
WO2015042423A3 (en) 2016-07-28
CA3174897A1 (en) 2015-03-26
AU2025202708A1 (en) 2025-05-08
KR20190009840A (ko) 2019-01-29
US20210170013A1 (en) 2021-06-10
JP2019167356A (ja) 2019-10-03
JP6667704B2 (ja) 2020-03-18
CN109675029A (zh) 2019-04-26
RU2016109925A (ru) 2017-10-24
RU2019128164A (ru) 2019-10-10
AU2022275399B2 (en) 2025-05-08
CA3005608C (en) 2020-06-30
US20250108103A1 (en) 2025-04-03
CL2016000650A1 (es) 2016-11-18
CA3005608A1 (en) 2015-03-26
JP7751438B2 (ja) 2025-10-08
CN105764525A (zh) 2016-07-13
AU2022268311A1 (en) 2022-12-15
CA2924526A1 (en) 2015-03-26
NZ757210A (en) 2022-12-23
ZA201601840B (en) 2022-09-28
PH12016500456A1 (en) 2016-05-16
JP2020007341A (ja) 2020-01-16
CA3174897C (en) 2025-10-07
JP2018203770A (ja) 2018-12-27
BR112016005948A2 (pt) 2017-09-26
RU2730011C2 (ru) 2020-08-14
WO2015042449A2 (en) 2015-03-26
ZA201903400B (en) 2024-09-25
CL2018000320A1 (es) 2018-06-08
WO2015042369A2 (en) 2015-03-26
WO2015042369A3 (en) 2015-07-02
JP2021073191A (ja) 2021-05-13
JP2022001581A (ja) 2022-01-06
JP7189410B2 (ja) 2022-12-14
KR20200039025A (ko) 2020-04-14
JP6586083B2 (ja) 2019-10-02
AU2020202147A1 (en) 2020-04-16
RU2016109925A3 (es) 2018-04-02
KR101943171B1 (ko) 2019-01-29
US20190038737A1 (en) 2019-02-07
AU2020202147B2 (en) 2022-12-08
US10953080B2 (en) 2021-03-23
EP3049105B1 (en) 2020-12-30
WO2015042423A2 (en) 2015-03-26
CA3060664A1 (en) 2015-03-26
AU2022275399A1 (en) 2023-01-05
AU2014321369A1 (en) 2016-03-17
MX2021012346A (es) 2021-11-04
KR102257743B1 (ko) 2021-05-28
JP2016534977A (ja) 2016-11-10
WO2015042449A3 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
ZA201903400B (en) Oil-based adjuvants
EP3668541A4 (en) FORMULATIONS FOR PNEUMOCOCCAL CONJUGATE VACCINE
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
EP3585803A4 (en) PNEUMOCOCCIC CONJUGATE VACCINE FORMULATIONS
IL283777A (en) Methods for formulating antibody drug conjugate compositions
MX2022014781A (es) Formulaciones de anticuerpos anti-pdl1.
MX2017015881A (es) Formulaciones para vacunas contra la neoplasia y metodos para preparar las mismas.
EP2995295A4 (en) OIL-BASED THICKENER, OIL-BASED THICKENING COMPOSITION AND COSMETIC PREPARATION
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
MX390278B (es) Formulaciones de vacuna de vial unico.
BR112017005524A2 (pt) segmentos de rna viral como agentes imunomoduladores e componentes de vacina
EP3636246A4 (en) COSMETIC PREPARATION WITH WATER-IN-OIL EMULSION
EP2825196A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
EP3603619A4 (en) VACCINAL ADJUVANT FORMULATION
MX2016006189A (es) Extracto de algas para su uso en calidad de agente inmunomodulador.
EA201590491A1 (ru) Иммуногенная композиция
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
SG11201911930SA (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
IT201700111990A1 (it) Scambiatore per uso medicale
TH167595A (th) วัคซีนหน่วยย่อย แอนติ-Mycoplasma Spp.
EA201691202A1 (ru) Флагеллин-содержащие белковые наночастицы в качестве платформы для вакцины
MA40186A (fr) Préparation capillaire de conditionnement, notamment shampooings contenant des silicones et des dérivés de guar quaternisés